CorePharma, LLC, a developer, manufacturer, and marketer of targeted generic prescription pharmaceuticals, has launched Methylphenidate Hydrochloride Tablets USP (“Methylphenidate”), the generic version of Novartis’ Ritalin. Methylphenidate is indicated for the treatment of narcolepsy and attention deficit disorders. CorePharma received final approval from the Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) on March 12, 2014. The product is available in the 5, 10, and 20 mg strengths and has begun shipping.
The methylphenidate immediate release tablet market had US sales of approximately $243 million according to IMS data as of December 2013.
